Supera交织镍钛支架与裸镍钛支架治疗股腘动脉病变的倾向评分匹配比较:XLPAD注册研究
基于XLPAD注册的回顾性研究,871例股腘动脉球囊扩张支架患者中Supera组118肢、裸镍钛支架组753肢,经1:1倾向评分匹配后比较1年结局。匹配后Supera组1年靶肢体血运重建率显著低于裸镍钛支架组(7.6% vs 13.6%,p=0.04),靶血管血运重建率差异未达统计学意义(7.6% vs 12.7%,p=0.08),全因死亡率相似。
要点
- 匹配后Supera支架1年靶肢体血运重建率显著低于裸镍钛支架(7.6% vs 13.6%,p=0.04)
- 匹配后两组1年靶血管血运重建率差异无统计学意义(7.6% vs 12.7%,p=0.08)
- Supera支架伸长>10%标称长度与1年靶肢体血运重建风险无显著关联(p=0.6)
核心结论
- 在股腘动脉介入中,使用Supera支架与裸镍钛支架相比,在未匹配和匹配队列中均与1年靶肢体血运重建风险降低相关。
研究设计与样本
- 回顾性研究,利用XLPAD注册(NCT01904851)数据,纳入2006年1月至2016年12月接受股腘动脉球囊扩张并置入Supera支架(118肢)或当代裸镍钛支架(753肢)的871例患者。
- 采用最近邻法进行1:1倾向评分匹配,基线人口学和临床特征匹配后形成118例裸镍钛支架匹配队列。
- 另进行核心实验室分析测量Supera支架展开长度。
主要发现
- 未匹配数据中,Supera组靶血管血运重建率数值上低于裸镍钛支架组(7.6% vs 13.4%,p=0.08),1年靶肢体血运重建率显著更低(7.6% vs 16.2%,p=0.02),1年死亡率相似(2.5% vs 2.7%,p=0.9)。
- Kaplan-Meier分析显示Supera组靶血管血运重建(p=0.02)和靶肢体血运重建(p=0.002)风险显著低于裸镍钛支架组。
- 倾向匹配后,Supera组1年靶血管血运重建估计值较低(7.6% vs 12.7%,p=0.08),靶肢体血运重建显著更低(7.6% vs 13.6%,p=0.04)。
- Supera支架伸长(>10%标称支架长度)与1年靶肢体血运重建风险无统计学显著关联(p=0.6)。
关键数值与推荐
- 未匹配队列1年靶肢体血运重建率:Supera组7.6% vs 裸镍钛支架组16.2%(p=0.02)。
- 匹配队列1年靶肢体血运重建率:Supera组7.6% vs 裸镍钛支架组13.6%(p=0.04)。
- 匹配队列1年靶血管血运重建率:Supera组7.6% vs 裸镍钛支架组12.7%(p=0.08)。
- Supera支架伸长>10%标称长度与1年靶肢体血运重建风险无关(p=0.6)。
临床怎么用
- 股腘动脉病变行球囊扩张支架置入时,选择Supera交织镍钛支架可能降低1年靶肢体血运重建风险。
- Supera支架置入后伸长超过标称长度10%未显示与1年靶肢体血运重建风险升高相关。
局限性
- 本研究为基于注册数据的回顾性研究,即使经倾向评分匹配仍可能存在未测量混杂。
- Supera组样本量较小(118肢),匹配后仅118例,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report a propensity score analysis comparing outcomes of the Supera interwoven nitinol stent to bare nitinol stents (BNS) in the femoropopliteal segment. Materials and Methods: A retrospective study was conducted utilizing data extracted from the Excellence in Peripheral Artery Disease (XLPAD) registry (ClinicalTrials.gov identifier NCT01904851) on 871 patients (mean age 65.1 years; 713 men) who underwent femoropopliteal balloon angioplasty with either Supera stent implantation in 118 limbs or other contemporary BNS in 753 limbs between January 2006 and December 2016. All patients in both groups were matched for baseline demographic and clinical characteristics in a 1:1 propensity score matching using the nearest neighbor method to create the 118-patient matched BNS cohort. One-year outcomes included all-cause mortality, target vessel revascularization (TVR), and target limb revascularization (TLR). An additional core laboratory analysis was conducted to measure the deployed length of Supera stents. Results: In unmatched data, the Supera stent group had a numerically lower rate of TVR (7.6% vs 13.4%, p=0.08) and a significantly lower 1-year TLR rate (7.6% vs 16.2%, p=0.02) compared to the BNS group. Both groups had similar 1-year mortality (2.5% vs 2.7%, p=0.9). Kaplan-Meier analysis demonstrated that the Supera group had a significantly lower risk of TVR (p=0.02) and TLR (p=0.002) than the BNS group. After propensity matching, the 1-year TVR estimate was lower for Supera stents (7.6% vs 12.7%, p=0.08) and significantly lower for TLR (7.6% vs 13.6%, p=0.04) than the BNS group. There was no statistically significant association between Supera stent elongation (>10% of the labeled stent length) and 1-year risk of TLR (p=0.6). Conclusion: Supera stent usage in femoropopliteal intervention was associated with reduced risk of 1-year repeat target limb revascularization compared with BNS treatment in both unmatched and matched cohorts.
引用
- Armstrong EJ, Jeon-Slaughter H, Kahlon RS, et al. Comparative Outcomes of Supera Interwoven Nitinol vs Bare Nitinol Stents for the Treatment of Femoropopliteal Disease: Insights From the XLPAD Registry. J Endovasc Ther. 2019. PMID: 31686573. doi:10.1177/1526602819885652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。